Who we help / Pharma & Biotech Commercial
Expand access to your approved advanced therapy
Current Health gives pharma and biotech companies the safety, operating, and evidence infrastructure to broaden patient access to approved advanced therapies: 24/7 nurse support for patients and caregivers through the at-risk window after infusion or across step-up dosing, seamlessly integrated monitoring technology, readiness support for treatment centers and community practices that choose to take part, and consented, deidentified real-world evidence.
1,500+
advanced therapy episodes
90%
of CAR-T therapies moved to outpatient at Sarah Cannon
80%
of patient issues resolved without site escalation
13+
advanced therapy assets supported
How we partner
Three ways to work with Current Health
After approval, sponsors work with us in three ways, and each one runs on the same model and nurses and adds to the evidence base.
Phase IV and implementation
Post-approval studies
Studies that show how your therapy performs outside the academic center, measuring outpatient and community delivery, hospital use, and patient experience to support label and site-of-care expansion.
After the prescription
Patient support programs
The clinical layer inside your existing program, covering the highest-risk days after each dose, with outcomes reported back to you.
Launch and growth
Access expansion programs
A sponsored opt-in service. You fund monitoring and 24/7 clinical cover for an agreed number of patients at an agreed set of treating sites, and we get each site ready to offer your therapy.
The access gap
Most eligible patients never receive an advanced therapy
Treatment is concentrated in a small number of academic centers. Distance, bed capacity, and the need for close monitoring after each dose keep many patients from ever being referred, and limit how far a therapy can reach after approval. The gap is growing, with close to 180 advanced therapies expected to be approved by 2030.
105,000+
patients a year expected to be treatable with advanced therapies by 2032
Cardinal Health 2026
40%
less likely to receive CAR-T for patients living 2–4 hours from a treatment center
Ahmed et al., Transplant Cell Ther. 2024
~85%
of US cancer patients receive care in community settings, not academic medical centers
National Cancer Institute
After approval
How we help expand access to your therapy
The site capacity, around-the-clock coverage, and evidence that drive adoption after launch.
Patient support programs
24/7 nurse support and monitoring technology through the at-risk window
Our nurses and technology support patients and caregivers day and night after CAR-T infusion, or from the first bispecific step-up dose through the first full dose, at home or in lodging near the treating center.
Access expansion programs
Monitoring and nurse coverage for sites that choose to take part
Treatment centers already running outpatient programs, and community practices closer to patients, can add monitoring and 24/7 nurse coverage through your therapy's at-risk window.
Evidence
Real-world evidence for payer and site-of-care decisions
With patient consent, the programs you fund produce deidentified data on how your therapy performs in outpatient and community settings, for your medical affairs, HEOR, and market access teams.
Patient support programs
24/7 clinical support for patients and caregivers through the highest-risk days
We help your program tackle access and affordability. Our 24/7 nurses support patients through the highest-risk days after each dose, under the treating site’s protocols, so they can be treated outpatient or at a community site near them, with less travel and time away from home. Outcomes are reported back to you.
01
Treatment closer to home
With nurses supporting them at home day and night, patients can be treated outpatient or in their community instead of traveling to an academic center for days of observation.
02
Patients stay on therapy
Side effects are recognized early and managed under the site’s protocol, so fewer patients stop treatment or are admitted unnecessarily.
03
Treating teams stay in control
Sites set eligibility, protocols, escalation, and site of care. Teams learn one standard across therapies.
04
Outcomes come back to you
We agree on outcome measures with you up front. Results are reported as consented, deidentified, aggregate data to your medical affairs, HEOR, and market access teams, for payer and site-of-care evidence.
Market expansion programs
More sites ready to treat, sooner
Through a sponsor-funded program that treatment centers and community practices choose to join, we put monitoring and 24/7 nurse coverage around their patients through your therapy's at-risk window. Eligible patients can then be treated outpatient or closer to home.
Each program covers an agreed number of patients and monitoring days, sized to your therapy's clinical at-risk window. We handle implementation, training, go-live, and logistics for the patient-facing service, and each site keeps a named on-call clinician for escalation.
48%
of oncology clinicians and administrators surveyed spent one to two years getting ready to administer advanced therapies
Cardinal Health 2026 survey
70%
of respondents name after-hours triage as a top patient support need, and 65% at-home and remote monitoring
Cardinal Health 2026 survey
Site identification and recruitment
We help you identify treatment centers and community practices that meet your therapy's site requirements, and support each site that chooses to take part from first conversation to go-live.
Site readiness
Site enablement that shortens the path to first patient: program build, preparation for FACT accreditation, and support with REMS certification where it applies, payer site-of-care approvals, and your site qualification. FACT, payers, and your team make their own decisions.
Configured to the asset
Monitoring matched to your therapy's labeled toxicities and their timing, from bispecific step-up dosing to outpatient CAR-T, where the product's labeling and the treating team's protocols allow. Our nurses assess CRS, ICANS, infection, hypotension, and neurologic and cardiac symptoms, including later-onset neurotoxicity where your label calls for it, and escalate under the treating team's protocols. Lab-defined toxicities, such as cytopenias and IEC-HS, stay with the treating team's lab schedule.
24/7 clinical coverage
Our Clinical Coordination Center supports patients and caregivers around the clock through the at-risk window, documents every contact, and escalates to the site's named on-call clinician when the treating team's protocols call for it.
Fully managed logistics
Our in-house team handles kit shipping, collection, reprocessing, and inventory, so site teams never have to manage devices or deliveries.
Evidence from every site
Consented, deidentified physiologic and clinical data from outpatient delivery, with quality, utilization, and patient experience metrics for each site reported to your medical affairs and HEOR teams.
Why Current Health
A partner from first trial to commercial scale
One platform across the lifecycle
An FDA-cleared, CE-marked platform that carries a therapy from Phase I trials through commercial delivery.
A published evidence base
60 peer-reviewed papers and abstracts since 2023, with the outpatient model validated across five CAR-T products and multiple sites.
An end-to-end partner
A 24/7 Clinical Coordination Center and in-house kit logistics, so sites and sponsors get delivery infrastructure along with the technology.
Built for older, frail patients
Median wearable adherence of 95.3% in patients aged 75+, higher than in younger patients. NHS virtual wards, 857 patients · Pugmire et al., Age and Ageing, 2024.
Our research
Built on leading research
Our clinical research team works with leading cancer centers to define, test, and publish how advanced therapies can be delivered safely outside the hospital, with 60 peer-reviewed papers and abstracts since 2023.
Outpatient CAR-T across a multisite network1
90%+
of CAR-T therapies delivered in the outpatient setting
Outpatient step-up dosing for bispecific T-cell engagers2
89%
of patients who began step-up dosing outpatient reached full dose
Earlier CRS recognition with continuous monitoring3
7 hrs
median earlier recognition of CRS than standard inpatient nursing care
Want to make your advanced therapy more accessible?
From a first trial to scaling access in the community, we’ll help you find the right starting point.